Corvus Pharmaceuticals

Bewertungs-Analyse

Über das Unternehmen

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development of product candidates that precisely target proteins that are critical to immune cell maturation and function in the United States. The company's lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1b/2 clinical trial for the treatment of peripheral T cell lymphoma, atopic dermatitis, hidradenitis suppurativa, autoimmune lymphoproliferative syndrome, and solid tumors monotherapy, and asthma, diseases. It also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of first line renal cell cancer; an

Trading-Daten

Ähnliche Aktien aus dem Sektor

Wo kann ich Corvus Pharmaceuticals kaufen?

Vergleiche die besten Broker — niedrige Gebühren, seriöse Anbieter, reguliert.